BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BCD-281 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BCD-281\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07321093-7129@assetmemo.bio
DTSTAMP:20261121T004524Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BCD-281: Phase 3 readout est. (NCT07321093)
DESCRIPTION:BCD-281\, phase 3\, Multiple Sclerosis.\nStudy: A Study of the 
 Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multip
 le Sclerosis\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bcd-281#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07321093
URL:https://assetmemo.bio/drug/bcd-281#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
